You are using an outdated browser. Please upgrade your browser to improve your experience and security.

AML quick facts

Learn key facts and statistics about acute myeloid leukemia (AML).

What is AML?


Types of secondary AML (sAML)


Approximately 30% of all AML cases are diagnosed as t-AML or AML-MRC.

Proper diagnosis of AML is determined by your doctor after reviewing symptoms, completing a bone marrow biopsy and blood cell count, and running certain tests.

68 years 68 years

The average age of an AML patient is 68 years old.


Risk factors and symptoms of AML


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.